SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-289252
Filing Date
2022-11-21
Accepted
2022-11-18 20:00:51
Documents
19
Period of Report
2022-11-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d389175d8k.htm   iXBRL 8-K 32034
2 EX-1.1 d389175dex11.htm EX-1.1 225046
3 EX-5.1 d389175dex51.htm EX-5.1 11116
4 EX-99.1 d389175dex991.htm EX-99.1 9401
8 GRAPHIC g389175dsp4.jpg GRAPHIC 8530
9 GRAPHIC g389175dsp7.jpg GRAPHIC 8530
10 GRAPHIC g389175newwdsp4.jpg GRAPHIC 2288
11 GRAPHIC g389175page6.jpg GRAPHIC 4252
  Complete submission text file 0001193125-22-289252.txt   510165

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA gthx-20221117.xsd EX-101.SCH 2872
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20221117_lab.xml EX-101.LAB 18758
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20221117_pre.xml EX-101.PRE 11725
13 EXTRACTED XBRL INSTANCE DOCUMENT d389175d8k_htm.xml XML 3472
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 221403259
SIC: 2834 Pharmaceutical Preparations